Peter N. Morcos

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 392 citations · Full text

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Edward Gane, Stuart K. Roberts, Catherine AM Stedman et al. · The Lancet · 2010 · 335 citations

Hepatology, Hepatitis C, Viral Hepatitis +9

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 252 citations · Full text

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam et al. · Antimicrobial Agents and Chemotherapy · 2012 · 43 citations · Full text

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Martin Hutchings, Gloria Iacoboni, Franck Morschhauser et al. · Blood · 2018 · 32 citations